Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
178
Shown on this page
12
Current sort
Recently updated
Therapy scope
Tirzepatide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Tirzepatide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 121–132 of 178 matching trials for Tirzepatide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 4 Interventional

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

NCT06801015
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155
View directory record Official record
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Active, not recruiting Phase 2 Interventional

The Long COVID Treatment Trial

NCT07128082
View directory record Official record
Conditions
Long COVID
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

NCT05433584
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Antihyperglycemic medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Canoga Park, California • Huntington Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

NCT06533527
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Interventions
GLP-1 medication
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

NCT05822830
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting Phase 2Phase 3 Interventional

Tailored Exercise Training Study Among Adults With HFpEF

NCT07223242
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Interventions
Moderate-intensity continuous training (MCT), Resistance training, Weight loss
Behavioral · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

A Study of LY3841136 in Overweight and Obese Participants

NCT06345066
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, LY3841136, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

NCT07096063
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
887,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

NCT07088718
View directory record Official record
Conditions
Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
44,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Alcohol Use Disorder

NCT06994338
View directory record Official record
Conditions
Alcohol Use Disorder, Obesity and Overweight, Alcohol
Interventions
Tirzepatide, Placebo injections
Drug
Lead sponsor
University of Southern California
Other
Eligibility
21 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

NCT06890611
View directory record Official record
Conditions
Healthy
Interventions
Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 20, 2026, 5:30 AM EDT

About this Tirzepatide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Tirzepatide.